Skip to main content

Table 1 Multivariable logistic regression analyses predicting PrEP discussion with peers

From: Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians

  ALL GENDERSa
N = 166/1405
FEMALEb
n = 43/379
MALEc
n = 119/1009
  N (%) AOR (95% CI) p-value n (%) AOR (95% CI) p-value n (%) AOR (95% CI) p-value
Age (years)
 < 30 12 (16.7) 1.5 0.7–2.9       8 (17.8) 1.3 0.5–3.0 0.568
 30–40 45 (16.7) 1.6 1.0–2.3 0.034      32 (18.1) 1.7 1.1–2.8 0.026
 > 40 109 (10.2) 1        79 (10.0) 1   
Socio-economic category
 Without occupation 30 (11.3) 1    7 (6.2) 1    21 (14.8) 1   
 Farmers/Intermediary workers 47 (9.4) 0.9 0.5–1.4 0.659 12 (10.7) 1.7 0.6–4.7 0.316 33 (8.5) 0.6 0.3–1.1 0.087
 Employee/Intellectual workers 72 (16.9) 1.7 1.0–2.7 0.036 19 (17.8) 3.8 1.4–10.2 0.007 53 (16.7) 1.2 0.6–2.1 0.608
 Retired 17 (8.1) 0.8 0.4–1.6 0.549 5 (10.6) 1.7 0.5–6 0.395 12 (7.3) 0.6 0.3–1.3 0.189
Member of HIV associations
 Yes 51 (21.3) 2.4 1.6–3.5 <0.001 11 (19.0) 2.4 1.1–5.4 0.028 37 (21.1) 2.4 1.6–3.8 <0.001
Undetectable HIV RNA
 No      14 (20.3) 2.5 1.1–5.3 0.023     
Route of HIV transmission
 Heterosexual intercourse 41 (8.7) 1        19 (7.7) 1   
 Homo/Bisexual intercourse 74 (15.8) 1.7 1.1–2.6 0.015      66 (15.4) 1.8 1.0–3.1 0.041
 Intravenous Drug Use 32 (14.0) 2.0 1.2–3.4 0.008      22 (12.9) 2.0 1.0–4.0 0.038
 Other/unknown 19 (7.9) 1.0 0.5–1.7 0.967      12 (7.4) 1.0 0.5–2.2 0.915
CD4 count/mm3
 < 200 21 (17.9) 2.1 1.2–3.7 0.009 7 (19.4) 2.9 1.0–8.5 0.050     
 200–499 45 (12.0) 1.2 0.8–1.8 0.325 12 (12.5) 1.5 0.7–3.6 0.308     
 500+ 75 (11.2) 1    16 (8.2) 1       
 NR/ND 25 (10.4) 1.2 0.7–2.0 0.501 8 (15.4) 2.1 0.8–5.8 0.144     
Partners’ number (last 3 months)
 No partner 39 (8.8) 1    14 (9.2) 1    25 (8.6) 1   
 Single partner 86 (11.7) 1.2 0.8–1.8 0.490 24 (11.2) 1.3 0.6–2.7 0.545 61 (11.8) 1.3 0.8–2.1 0.347
 Multiple partners 41 (18.1) 1.7 1.0–2.9 0.042 5 (45.5) 8.9 2.1–37.7 0.003 33 (16.4) 1.6 0.9–3.0 0.096
  1. AOR adjusted odds ratio, CI confidence interval, ART antiretroviral therapy, STI sexually transmitted infection
  2. aIncluding Transgender persons (n = 4/17). Significant variables at univariate analysis (p < 0.100): Gender (forced variable); Age; Socio-economic category; Member of HIV associations; Route of HIV transmission; CD4 count/mm3; STI (last 12 months); Partners’ number (last 3 months)
  3. bSignificant variables at univariate analysis (p < 0.100): Age (forced variable); Socio-economic category; Member of HIV associations; Undetectable HIV RNA; CD4 count/mm3; Partners’ number (last 3 months)
  4. cSignificant variables at univariate analysis (p < 0.100): Age; Place of residence; Socio-economic category; Member of HIV associations; Route of HIV transmission; Partners’ number (last 3 months)